Scholarlink

<p>The continued evolution of SARS-CoV-2 variants that evade immunity highlights a need to develop vaccines that elicit variant-specific antibodies and neutralize emerging strains. However, immune imprinting from antecedent SARS-CoV-2 exposure can limit the generation of such antibodies. Here, we evaluate strategies to enhance variant-specific antibody responses in female mice primed with Wuhan-1 spike-based mRNA or chimpanzee adenoviral-vectored (ChAd) vaccines and boosted with Omicron variant-matched vaccines. Altering the intramuscular injection site did not substantially affect variant-specific serum antibody responses. However, increasing booster antigen doses, performing repeated boosters, and administering booster vaccines intranasally enhanced variant-specific responses against the vaccine-matched Omicron strain. Boosting intranasally with a ChAd vaccine encoding the spike protein of Omicron XBB.1.5 elicited stronger XBB.1.5-specific responses in serum, bronchoalveolar lavage fluid, and draining lymph nodes than intramuscular boosting with the same vaccine. Regardless of booster regimen, neutralizing activity against XBB.1.5 was predominantly mediated by antibodies that were non-reactive to Wuhan-1 spike. These findings establish that in mice, intranasal or repeated variant-matched boosting can overcome the effects of imprinting and enhance immunity against SARS-CoV-2 strains.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Intranasal boosting induces variant-specific responses in SARS-CoV-2 vaccine-imprinted mice

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月27日

查看全文
  • Chieh-Yu Liang,
  • Suzanne M. Scheaffer,
  • James Brett Case,
  • Igor P. Dmitriev,
  • Yuhao Li,
  • Sameer Kumar Malladi,
  • Xinyi Liu,
  • Baoling Ying,
  • Pritesh Desai,
  • Sean P. J. Whelan,
  • David T. Curiel,
  • Ali H. Ellebedy,
  • Michael S. Diamond

摘要

The continued evolution of SARS-CoV-2 variants that evade immunity highlights a need to develop vaccines that elicit variant-specific antibodies and neutralize emerging strains. However, immune imprinting from antecedent SARS-CoV-2 exposure can limit the generation of such antibodies. Here, we evaluate strategies to enhance variant-specific antibody responses in female mice primed with Wuhan-1 spike-based mRNA or chimpanzee adenoviral-vectored (ChAd) vaccines and boosted with Omicron variant-matched vaccines. Altering the intramuscular injection site did not substantially affect variant-specific serum antibody responses. However, increasing booster antigen doses, performing repeated boosters, and administering booster vaccines intranasally enhanced variant-specific responses against the vaccine-matched Omicron strain. Boosting intranasally with a ChAd vaccine encoding the spike protein of Omicron XBB.1.5 elicited stronger XBB.1.5-specific responses in serum, bronchoalveolar lavage fluid, and draining lymph nodes than intramuscular boosting with the same vaccine. Regardless of booster regimen, neutralizing activity against XBB.1.5 was predominantly mediated by antibodies that were non-reactive to Wuhan-1 spike. These findings establish that in mice, intranasal or repeated variant-matched boosting can overcome the effects of imprinting and enhance immunity against SARS-CoV-2 strains.